Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2006; 12(1): 66-69
Published online Jan 7, 2006. doi: 10.3748/wjg.v12.i1.66
Published online Jan 7, 2006. doi: 10.3748/wjg.v12.i1.66
Indication for H pylori eradication | Peptic ulcer |
Regardless of the stage of ulcer | |
Low-grade MALT associated lymphoma | |
Stage IE1 | |
After endoscopic mucosal resection (EMR) of early gastric cancer (EGC) | |
Recommended first line therapy | PPI-based triple therapy for 1-2 wk |
- PPI (omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg) b.i.d. | |
- Amoxicillin (not ampicillin) 1 000 mg b.i.d. | |
- Clarithromycin (or metronidazole) 500 mg b.i.d. | |
Follow-up after eradication therapy | Urea breath test: test of choice, if available |
Or both biopsy urease test and histology | |
At least 4 wk after completion of therapy | |
Serology: not useful to confirm the eradication | |
Recommended second-line therapy | Quadruple therapy for 1 wk |
(PPI+conventional bismuth-based triple therapy) | |
- PPI (omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg) b.i.d. | |
- Denol 120 mg b.i.d. | |
- Metronidazole 400-500 mg t.i.d. | |
- Tetracycline 500 mg q.i.d |
-
Citation: Kim BG, Kim JW, Jeong JB, Jung YJ, Lee KL, Park YS, Hwang JH, Kim JU, Kim NY, Lee DH, Jung HC, Song IS. Discrepancies between primary physician practice and treatment guidelines for
Helicobacter pylori infection in Korea. World J Gastroenterol 2006; 12(1): 66-69 - URL: https://www.wjgnet.com/1007-9327/full/v12/i1/66.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i1.66